HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: February,

Slides:



Advertisements
Similar presentations
Click the arrows to advance forward and backward. Click the Next link below to advance to the assessment. The A B C & D’s of Suicide Assessment and Clinical.
Advertisements

PSYC 342: Psychopharmacology
Pharmacological strategies for early stages of schizophrenia Russell L. Margolis, M.D. Johns Hopkins Clinical Schizophrenia Program NAMI Maryland Conference.
Schizophrenia in Teenagers and Young Adults From the Johns Hopkins Clinical Schizophrenia Program: Russell L. Margolis, M.D. Krista Baker, LCPC Tom Sedlak,
DUR Board Meeting March 12, 2008 West Virginia Department of Health and Human Resources Bureau for Medical Services Drug Utilization Review Board.
PRELIMINARY DRAFT Behavioral Health Transformation September 26, 2014 PRELIMINARY WORKING DRAFT, SUBJECT TO CHANGE.
Arkansas Children’s Behavioral Health Care Commission AR DHS Division of Medical Services Pharmacy Program Laurence H. Miller, M.D., Senior Psychiatrist.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
Developed by Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: September 2009 Most recently updated: October 2013.
The Antipsychotic Atlas Project - Overview Kennedy, J (PI); S Murphy; S McPherson & M Layton (co-Is) Start date: 9/13End date: 8/15 This research project.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
Documentation for Acute Care
Series 1: Meaningful Use for Behavioral Health Providers 9/2013 From the CIHS Video Series “Ten Minutes at a Time” Module 5: Clinical Quality Measures.
© Copyright 2011, Pearson Education, Inc. All rights reserved. Chapter 15 Drugs for Treating Schizophrenia and Mood Disorders.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 31 Antipsychotic Agents and Their Use in Schizophrenia.
Referral to Treatment Referral.
Psychiatric Services in an Emergency Department Prepared by: Kathleen Crapanzano, MD DHH, OMH Medical Director Presented by: Patricia Gonzales, LCSW Acting.
Youth Empowerment Services (YES) A Medicaid Waiver Program for Children with Severe Emotional Disturbances Clinical Eligibility Determination Texas Department.
Stroke Quality Measures Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: May, 2012 Most recently updated: October,
SBIRT: Screening, Brief Intervention and Referral to Treatment Overview, Epidemiology and Evidence.
Antipsychotic Medications in the Primary Care Practice Angelo Potenciano, M.D.
Older Adults Legal & Ethical Basis for Practice Settings for Psychiatric Care Chapters 25, 26, 27.
Community Health Team Care Management Process PinnacleHealth Systems Don DeArmitt, M.D. Becky E. Zook RN, BSN, MS, CCP.
Increase the Proportion of Metabolic Syndrome Screening In Adults with Severe Mental Illness receiving "atypical” second generation antipsychotics.
1 Just The Facts Ma’am Dementia Care & Anti-Psychotics Just The Facts Ma’am December 17, 2012 Ronald A. Savrin, MD, MBA, FACS Medical Director, Ohio KePRO.
Geriatric Psychiatry Services JoAnn Pelletier-Bressette, RN, Nurse Manager Nancy Hooper, BScN, RN, CPMHN (C) 1.
Schizophrenia By Azlynn Williams Block 4 3/3. What is this disease??? When you think of crazy, you think of Schizophrenia.
A-MOP: An Antipsychotic Medication Optimization Program for Long Term Care Fiona Sudbury, RN, Director of Care Duncan Robertson, Chief of Medical Staff.
1 Governor’s Office of Health Policy and Finance MaineCare Pharmacy Initiatives.
Using Recent Research to Improve the Cost-Effectiveness of VA Antipsychotic Formulary Policy Robert Rosenheck MD Michael Sernyak MD New England MIRECC.
Antipsychotic Utilization: Oregon State Medicaid Ann M. Hamer, PharmD BCPP This presentation was made possible by a grant from the State Attorney General.
Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents Sandhya Mehta, MS; Hua Chen, MD, PhD; Michael Johnson, PhD; and Rajender R. Aparasu,
WHAT IS THE EVIDENCE ON EFFECTIVENESS OF ANTIPSYCHOTICS IN PERSONS WITH DEMENTIA? 1.
Medical Care. Antipsychotic medications mainstay of treatment for schizophrenia 2 Types of Antipsychotics Conventional or 1 st generation – Dopamine 2.
*a group of severe brain disorders in which people interpret reality abnormally *may result in hallucinations, delusions, and disordered thinking and.
Comprehensive Transition Planning During the Hospital Stay RARE Mental Health Collaborative Learning Day February 19, 2014 Dr. Paul Goering VP Mental Health.
Affective Disorders. Who can tell me how many people suffer in America from bipolar disorder?” About 2 million people suffer and that is starting at 18.
Use of Antipsychotic Drugs in Dementia Josepha A. Cheong, MD University of Florida Departments of Psychiatry and Neurology Chief, Division of Geriatric.
Urine Drug Monitoring: Indiana Council of Community Mental Health Centers Jerry Vaccaro, M.D. President, Ingenuity Health October 15, 2015.
Mental Health Nursing: Pharmacology: Antipsychotic Medications C. Calzolari 2016.
for MHD & Therapeutics is proud to present And Now Here Is The Host... Dr. Schilling.
Tutorial ANTIPSYCHOTICS/ NEUROLEPTICS. Pharmacological Interventions Antipsychotic medications First Generation (Typicals) Includes phenothiazines, thioxanthenes,
First-Generation Versus Second- Generation Antipsychotics in Adults: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality.
Schizoaffective Disorder Hannah Allegretto University of Pittsburgh School of Pharmacy PharmD Candidate 2013.
Central Nervous System PART 2. Anticonvulsants Uses  Epilepsy:  Seizures accompanied by loss or disturbance of consciousness and possibly abnormal.
Managed Care Nursing Facility Quality Initiatives February 2, 2015.
Antipsychotic Medications: Prevalence of Inappropriate Use, Polypharmacy, and Non-Adherence Nancy G. Pham, PharmD; Lisa Le, MS; Karen M. Stockl, PharmD;
Purpose Of Training: To guide Clinicians in the completion of screens and development of Alternative Community Service Plans.
© Copyright 2011, Pearson Education, Inc. All rights reserved. Psychotropic Medication: Overview 1.0 CEU Presented by Dr. Jeremy Burd MD Medical Director.
Drugging Dementia: Anti-Psychotropic Drug Use in ALFs and Legal Implications Program prepared by Suzanne Suarez Hurley, Esq., R.N., B.S.N., L.H.R.M.
Answers To Your Questions About Tardive Dyskinesia
Addressing Partial-Response or Non-Response
Antipsychotic Agents and Their Use in Schizophrenia
Bipolar Disorder.
Answers to Your Questions About Tardive Dyskinesia
Schizophrenia’s Heterogeneity
Central Nervous System
TÂM THẦN PHÂN LIỆT (Schizophrenia).
Antipsychotic Agents and Their Use in Schizophrenia
Chapter 7 The Nursing Process and Standards of Care in Psychiatric Mental Health Nursing.
Pharmacogenetic testing:
Hospital Based Inpatient Psych Care
Lurasidone Flavio Guzmán, MD.
Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD.
Antipsychotics: The Essentials Module 1 Introduction
West Virginia Bureau for Medical Services (BMS)
Utilization of the Ingenuity Health Medication Monitoring Program at Center for Health Care Services Roberto Jimenez, M.D. Denise Canchola, D.N.P.
Long Acting Injectable Antipsychotic Medication
Certified Community Behavioral Health Clinic
Topic Discussion By Alexandria Brown
Presentation transcript:

HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: February, 2013 Most recently updated: November 2013

The Psychiatric Measure Set  CMS has maintained 6 of the original measures for inpatient behavioral health units.  Starting with discharges of January 1, 2014, one new measure, alcohol use screening, has been added for data collection.

Also  A second measure, follow-up after hospitalization for mental illness, will be included in the measure set report but will be taken directly from claims submitted between July 1, 2013 and June  Each measure will be discussed on the following slides

Hours of Physical Restraint or Seclusion  As in other venues of health care, the use of restraint or seclusion is limited to situations where there is imminent danger of harm to the patient or others. The data collected reflects the total number of minutes the patient was either restrained or in seclusion therefore very exact charting is needed.

Alcohol Use Screening  Patients with substance abuse problems have a greater risk for serious injury and over 50 medical problems including hypertension, GI bleeding, depression, stroke, dementia, cirrhosis, some cancers, dysrhythmias and infection (NIAAA, 2005).  A 2004 report in JAMA identified that substance abuse (alcohol, drug or tobacco) accounted for one in four deaths in the USA (Mokdad, 2000).

Alcohol Use Screening  Each patient, 18 years of age or older admitted to an inpatient psychiatric unit must be screened for alcohol use within the first three days of admission.  Since hospitalization offers an opportunity to address substance use, this assessment should be referenced as the treatment plan is developed.

Multiple Antipsychotic Medication Usage  This measure focuses on the number of patients who are discharged from an inpatient psychiatric setting on 2 or more antipsychotic medications.  Research shows that antipsychotic polypharmacy often leads to greater side effects with no improvement in clinical outcomes.  The medications included in this measure are listed on the next 3 slides.

Oral/ Injectable Antipsychotic Medications Fanapt FazaClo Orally Disintegrating Tablets Fluphenazine Fluphenazine Decanoate Injectable Fluphenazine HCL Oral Solution Fluphenazine HCL Tablets Geodon Capsules Abilify Oral Solution Abilify Tablets Abilify Discmelt Antipsychotic Not Otherwise Specified (NOS) Aripiprazole Oral Solution Aripiprazole Tablets Asenapine Chlorpromazine Oral Solution Chlorpromazine Oral Syrup Chlorpromazine Tablets Clozapine Tablets Clozaril Tablets Etrafon Haldol Oral Solution Haldol Tablets Haloperidol Decanoate Injectable Long-Acting Haloperidol Oral Solution Haloperidol Tablets IIoperidone

Oral/ Injectable Antipsychotic Medications Invega Tablets Prolixin Tablets Invega sustenna Injection Latuda Loxapine Capsules Loxitane Capsules Lurasidone Mellaril Tablets Mesoridazine Navane Capsules Olanzapine + Fluoxetine Capsules Olanzapine Tablets Olanzapine ZYDIS Orally Disintegrating Tablets Orap Tablets Paliperidone Tablets Permitril Perphenazine Tablets Pimozide Tablets Prolixin Decanoate Injectable- Long Acting Prolixin Oral Solution Quetiapine Fumarate Quetiapine Tablets Risperal Consta Injectable- Long Acting Risperdal M-Tab Orally Disintegrating Tablets Risperdal Oral Solution Risperdal Tablets Risperidone Injectable - Long Acting Risperidone M- Tab Orally Disintegrating Tab. Risperidone Tablets Saphris

Oral/ Injectable Antipsychotic Medications  Serentil  Seroquel Tablets  Seroquel XR Tablets  Stelazine Tablets  Symbyax CapsulesThioridazine HCL Tablets  Thiothixene Capsules  Thorazine Oral Solution  Thorazine Oral Syrup  Thorazine Tablets  Triavil  Trifluroperazine HCL Tablets  Trilafon Tablets  Ziprasidone HCL Tablets  Zyprexa Tablets  Zyprexa ZYDIS Orally Disintegrating Tablets

Appropriate Justification for Multiple Antipsychotic Medications  Documentation needed for the appropriate justification for using multiple antipsychotic medications includes: 1. The patient has a history of a minimum of three failed trials of monotherapy. At minimum, the names of the medications used in the trials must be documented.

Appropriate Justification for Multiple Antipsychotic Medication 2. There is documentation of a recommended plan to taper to monotherapy or the cross-taper is in process at the time of discharge. This must include the names of the medications to be tapered 3. There is documentation of that the second antipsychotic medication was ordered to enhance the effectiveness of Clozapine.

Complete Discharge Continuing Care Plan  Every patient discharged must have a discharge plan that includes: 1. The reason for hospitalization 2. Principle discharge diagnosis 3. Discharge medications (dosage and indication for use). If no medications are ordered this must be documented. 4. Next level of care recommendations

Discharge Continuing Care Plan Transmission  There must be evidence that the discharge continuing care plan was transmitted to the next level of care provider.

Follow-up After Hospitalization For Mental Illness  This measure is obtained from claims submitted.  All patients ages six years or older who are discharged from an inpatient psychiatric unit are expected to have an outpatient visit, intensive outpatient encounter or partial hospitalization with a mental health practitioner.  The data will be reported for both follow-up within 7 days of discharge and 30 days of discharge.

Follow-up After Hospitalization For Mental Illness  While these visits are out of control of the inpatient unit, emphasis on the importance of ongoing care for mental illness should be included in the patient and family education while the person in hospitalized.

Test Your Knowledge 1. The inpatient psychiatric measures only apply to the geriatric patients. A. True B. False

Test Your Knowledge 2. Restraints and seclusion event documentation should include what triggered the action and exactly how long (in minutes) the patient is restricted. A. True B. False

Test Your Knowledge 3. If the patient is discharged on _______ or more antipsychotic medications there must be documented justification in the medical record. A. 2 B. 3 C. 4

Test Your Knowledge 4. The complete discharge continuing care plan for a patient discharged from an inpatient psychiatric unit include: A. The reason for hospitalization B. Principle discharge diagnosis C. Discharge medications D. Next level of care recommendations E. All of the above

Test Your Knowledge 5. You must complete an assessment for alcohol use for patients 18 years of age or older admitted to an inpatient psychiatric unit within ________ days of admission. A. one B. two C. three

References  Mokdad, A. et.al. Actual Causes of Death in the Untied Stated, JAMA 2004; 291:  (NIAAA) National Institute on Alcohol Abuse and Alcoholism. A clinician’s Guide, 2005 Edition, Rockville MD.

The End!!